Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Reduced Intensity Conditioning Transplants

Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation

Bone Marrow Transplantation volume 28, pages 341–347 (2001)Cite this article

Abstract

We compared the occurrence of severe infections following 71 reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell transplants (PBSCT) and 123 standard myeloablative PBSCT (MINI and STAND groups, respectively) from HLA-identical siblings. The probability of 1-year infection-related mortality (IRM) was 19% in the STAND group and 10% in the MINI group (log-rank, P = 0.3). On multivariate analysis the only significant variable associated with a higher risk of IRM was the development of moderate-to-severe GVHD (P = 0.005). The probability of developing CMV infection was 39% in the STAND group and 21% in the MINI group (P = 0.03) (43% and 21%, respectively, in seropositive donor/recipient pairs, P = 0.01), and the probability of developing CMV disease was 9.5% and 1%, respectively (P = 0.05) (11% and 1%, respectively, in seropositive donor/recipient pairs, P = 0.03). Multivariate analysis of CMV infection identified four variables associated with a higher risk: CMV positive serostatus (P = 0.05), STAND transplant group (P = 0.02), the development of moderate-to-severe GVHD (P < 0.001) and a dose of CD34+ cells infused below 6 × 106/kg (P = 0.01). Invasive fungal infections and pneumonias of unknown origin did not differ between groups, and neither did other severe non-CMV viral infections and bacterial infections. Our results suggest that RIC allogeneic PBSCT may decrease the risk of dying from an opportunistic infection and reduces the occurrence of CMV infection and disease. Overall, the development of GVHD (acute or chronic) is an important risk factor for these complications. Other infections continue to pose a significant threat to recipients of RIC allografts, stressing that prophylactic and supportive measures are an important aspect in their care. Bone Marrow Transplantation (2001) 28, 341–347.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  2. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  3. Khouri IF, Keating M, Körbling M et al. Transplant-lite. Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817–2824

    Article  CAS  PubMed  Google Scholar 

  4. Carella AM, Lerma E, Dejana A et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias Haematologica 1998 83: 904–909

    CAS  PubMed  Google Scholar 

  5. McSweeney P, Niederwieser D, Shizuru J et al. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and mycophenolate mofetil Blood 1999 94: (Suppl. 1) 393a

    Google Scholar 

  6. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 1999 94: 3234–3241

    CAS  PubMed  Google Scholar 

  7. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans Bone Marrow Transplant 2000 25: 345–350

    Article  CAS  PubMed  Google Scholar 

  8. Engels EA, Ellis CA, Supran SE et al. Early infections in bone marrow transplantation: Quantitative study of clinical factors that affect risk Clin Infect Dis 1999 28: 256–266

    Article  CAS  PubMed  Google Scholar 

  9. Blijlevens NMA, Donnelly JP, De Pauw BE . Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview Bone Marrow Transplant 2000 25: 1269–1278

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Parkman R, Weinberg KI . Immunological reconstitution following hematopoietic stem cell transplantation In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic Cell Transplantation 2nd edn Blackwell Scientific Publications: Boston, MA 1999 pp 704–711

    Google Scholar 

  11. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading Bone Marrow Transplant 1995 15: 825–828

    CAS  PubMed  Google Scholar 

  12. Martino R, Caballero MD, Canals C et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicenter study Br J Haematol (in press)

  13. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens Blood 1990 76: 1876–1871

    Google Scholar 

  14. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens Blood 1991 77: 1660–1665

    CAS  PubMed  Google Scholar 

  15. Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation Bone Marrow Transplant 2000 26: 251–255

    Article  CAS  PubMed  Google Scholar 

  16. Hensel N, Almeida K, Bahceci E et al. Factors affecting incidence and timing of cytomegalovirus reactivation after allogeneic peripheral blood stem cell transplants Blood 1999 94: (Suppl. 1) 337a

    Google Scholar 

  17. Chakrabarti S, Kottaridis P, Ogormon P et al. High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using CAMPATH (anti-CD52 antibody) Blood 2000 96: (Suppl. 1) 586a

    Google Scholar 

  18. Reddy V, Pollock BH, Sharda S et al. GVHD and CMV antigenemia after allogeneic peripheral blood stem cell transplantation: comparison between myeloablative and non-myeloablative (mini) conditioning regimens Blood 2000 96: (Suppl. 1) 191a

    Google Scholar 

  19. Small TN, Avigan D, Dupont B et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis Biol Blood Marrow Transplant 1997 3: 65–75

    CAS  PubMed  Google Scholar 

  20. Junghanss C, Boeckh M, Carter R et al. Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation Blood 2000 96: (Suppl. 1) 188a

    Google Scholar 

  21. Ringdén O, Nilsson B . Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose and splenectomy Transplantation 1985 40: 39–44

    Article  PubMed  Google Scholar 

  22. Mavroudis D, Fox M, Read EJ et al. Effect of CD34+ cell dose on outcome following T-depleted marrow transplantation Blood 1996 88: 3223–3229

    CAS  PubMed  Google Scholar 

  23. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemia burden, donor HLA-matching and marrow cell dose Blood 1997 89: 4226–4235

    CAS  PubMed  Google Scholar 

  24. Barrett AJ, Ringdén O, Zhang M-J et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia Blood 2000 95: 3323–3327

    CAS  PubMed  Google Scholar 

  25. Bahçeci E, Read E, Leitman S et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies Br J Haematol 2000 108: 408–414

    Article  PubMed  Google Scholar 

  26. Martino R, Rovira M, Carreras E et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a comparison of unmanipulated and CD34+ cell-selected transplantation (submitted for publication)

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain

    R Martino, C Canals, J Sierra & S Brunet

  2. Hospital Clínico Universitario de Salamanca, Barcelona, Spain

    MD Caballero, J San Miguel & J Pérez-Simon

  3. Department of Hematology, Hospital Clínic i Provincial, Barcelona, Spain

    M Rovira

  4. Hospital Clínico Universitario, Valencia, Spain

    C Solano

  5. Hospital Son Dureta, Palma de Mallorca, Spain

    J Bargay

  6. Hospital de Jerez de la Frontera, Barcelona, Spain

    A León

  7. Institut Catalá d'Oncología, Barcelona, Spain

    J Sarrá

  8. Hospital de la Princesa, Madrid, Spain

    R de la Camara

Authors
  1. R Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. MD Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Canals
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J San Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Solano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Bargay
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Pérez-Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A León
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Sarrá
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Brunet
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R de la Camara
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the alloPBSCT and Infectious/Non-infectious Complications Subcommittees of the Grupo Espanol de Trasplante Hematopoyetico (GETH)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martino, R., Caballero, M., Canals, C. et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 28, 341–347 (2001). https://doi.org/10.1038/sj.bmt.1703150

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703150

Keywords

This article is cited by

Search

Advanced search

Quick links